A glaucoma treatment system includes: a cannula body configured to be positioned in an area of Schlemms canal an illumination guide extending along the cannula body at least one drug source coupled to the cannula body a cross-linking agent source coupled to the cannula body and an illumination source coupled to the illumination guide. The at least one drug source includes a drug that promotes outflow of aqueous humor through the trabecular meshwork and into Schlemms canal. The cannula body delivers the drug from the at least one drug source to the area of Schlemms canal, and in response to changes in the outflow of aqueous humor, delivers the cross-linking agent to the area of Schlemms canal. The illumination guide delivers photo-activating light from the illumination source to the area of Schlemms canal. The photo-activating light activates the cross-linking agent, thereby stabilizing changes in the area of Schlemms canal.
